A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?
暂无分享,去创建一个
M. Eikermann | R. Banzi | A. Rath | S. Garattini | E. Neugebauer | V. Hivert | J. Jakobsen | M. Laville | J. Wetterslev | V. Bertele' | C. Gluud | J. Demotes-Mainard | B. Segrestin | S. Djurisic | C. Kubiak | Valérie Salamon | Sandra Peixoto
[1] I. van der Tweel,et al. Sequential designs with small samples: Evaluation and recommendations for normal responses , 2018, Statistical methods in medical research.
[2] D. Pieper,et al. Specific barriers to the conduct of randomised clinical trials on medical devices , 2017, Trials.
[3] C. la Vecchia,et al. Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with? , 2017, Trials.
[4] A. Rath,et al. Barriers to the conduct of randomised clinical trials within all disease areas , 2017, Trials.
[5] Tim Friede,et al. Meta‐analysis of few small studies in orphan diseases , 2016, Research synthesis methods.
[6] M. Parmar,et al. How do you design randomised trials for smaller populations? A framework , 2016, BMC Medicine.
[7] K. Roes. A framework: make it useful to guide and improve practice of clinical trial design in smaller populations , 2016, BMC Medicine.
[8] P. Gøtzsche,et al. “Adaptive pathways” to drug authorisation: adapting to industry? , 2016, British Medical Journal.
[9] K. Thorlund,et al. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review , 2016, BMJ Open.
[10] Christian Gluud,et al. Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them. , 2016, European journal of internal medicine.
[11] G. Rasi,et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice , 2016, British journal of clinical pharmacology.
[12] S. Garattini,et al. Letting post-marketing bridge the evidence gap: the case of orphan drugs , 2016, British Medical Journal.
[13] Ralf-Dieter Hilgers,et al. Directions for new developments on statistical design and analysis of small population group trials , 2016, Orphanet Journal of Rare Diseases.
[14] C. Sudlow,et al. Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review , 2016, Journal of biopharmaceutical statistics.
[15] J. Little,et al. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? , 2015, Genetics in Medicine.
[16] L. Billingham,et al. Research methods to change clinical practice for patients with rare cancers. , 2016, The Lancet. Oncology.
[17] D. Bolignano,et al. Good-quality research in rare diseases: trials and tribulations , 2016, Pediatric Nephrology.
[18] R. Valdez,et al. Public Health and Rare Diseases: Oxymoron No More , 2016, Preventing chronic disease.
[19] Martin Posch,et al. Evidence, eminence and extrapolation , 2016, Statistics in medicine.
[20] V. Volpert,et al. An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials. , 2016, Journal of Clinical Epidemiology.
[21] Peter A Merkel,et al. A small n sequential multiple assignment randomized trial design for use in rare disease research. , 2016, Contemporary clinical trials.
[22] Saul Perlmutter,et al. Blind analysis: Hide results to seek the truth , 2015, Nature.
[23] S. Goodman,et al. Meta-research: Evaluation and Improvement of Research Methods and Practices , 2015, PLoS biology.
[24] C. Tudur Smith,et al. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov , 2014, Orphanet Journal of Rare Diseases.
[25] Joshua J Gagne,et al. Innovative research methods for studying treatments for rare diseases: methodological review , 2014, BMJ : British Medical Journal.
[26] John P. A. Ioannidis,et al. How to Make More Published Research True , 2014, PLoS medicine.
[27] Elena Kulinskaya,et al. Trial sequential methods for meta‐analysis , 2014, Research synthesis methods.
[28] S. Simoens,et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. , 2014, Journal of comparative effectiveness research.
[29] Mohit Bhandari,et al. Blinded interpretation of study results can feasibly and effectively diminish interpretation bias. , 2014, Journal of clinical epidemiology.
[30] Harold Varmus,et al. Rescuing US biomedical research from its systemic flaws , 2014, Proceedings of the National Academy of Sciences.
[31] P. Williamson,et al. Methodology of clinical trials for rare diseases. , 2014, Best practice & research. Clinical rheumatology.
[32] J. Jakobsen,et al. The thresholds for statistical and clinical significance – a five-step procedure for evaluation of intervention effects in randomised clinical trials , 2014, BMC Medical Research Methodology.
[33] O. Gross,et al. Challenges for academic investigator-initiated pediatric trials for rare diseases. , 2014, Clinical Therapeutics.
[34] A. Hoes,et al. Drug development for exceptionally rare metabolic diseases: challenging but not impossible , 2013, Orphanet Journal of Rare Diseases.
[35] K. Bushby,et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases , 2013, Orphanet Journal of Rare Diseases.
[36] K. Boycott,et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.
[37] John P A Ioannidis,et al. Optimal type I and type II error pairs when the available sample size is fixed. , 2013, Journal of clinical epidemiology.
[38] Anne W. Riley,et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[39] D. Lacombe,et al. International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective , 2013, Ecancermedicalscience.
[40] Brian A. Nosek,et al. Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.
[41] Boris Freidlin,et al. Statistical Challenges in the Evaluation of Treatments for Small Patient Populations , 2013, Science Translational Medicine.
[42] Sylvie Chabaud,et al. Experimental designs for small randomised clinical trials: an algorithm for choice , 2013, Orphanet Journal of Rare Diseases.
[43] Roberta Joppi,et al. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU , 2012, European Journal of Clinical Pharmacology.
[44] Domenica Taruscio,et al. The need for worldwide policy and action plans for rare diseases , 2012, Acta paediatrica.
[45] M Mauer,et al. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size. , 2012, European journal of cancer.
[46] F. Dhombres,et al. Representation of rare diseases in health information systems: The orphanet approach to serve a wide range of end users , 2012, Human mutation.
[47] H. Eichler,et al. Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.
[48] Jianjun Gao,et al. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. , 2012, Intractable & rare diseases research.
[49] J. Demotes-Mainard,et al. A European perspective--the European clinical research infrastructures network. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] George A Tomlinson,et al. A framework for applying unfamiliar trial designs in studies of rare diseases. , 2011, Journal of clinical epidemiology.
[51] The Committee for Orphan Medicinal Products and the Eu Secretariat. European regulation on orphan medicinal products: 10 years of experience and future perspectives , 2011, Nature Reviews Drug Discovery.
[52] G. Molenberghs,et al. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials , 2010, Statistical methods in medical research.
[53] F. Rivas-Ruíz,et al. Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index , 2009, Trials.
[54] S. Garattini,et al. Orphan drug development is not taking off. , 2009, British journal of clinical pharmacology.
[55] P. Scardino,et al. The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost , 2009, Trials.
[56] K. Thorlund,et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. , 2008, Journal of clinical epidemiology.
[57] R. Koretz,et al. Hepatology may have problems with putative surrogate outcome measures. , 2007, Journal of hepatology.
[58] G Molenberghs,et al. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes , 2001, Statistics in medicine.
[59] P. Gøtzsche,et al. Blinding during data analysis and writing of manuscripts. , 1996, Controlled clinical trials.